Editas Medicine Capital Expenditures (CapEx) Growth & History (EDIT)
Editas Medicine's capital expenditures (capex) was $607,000 for fiscal 2025.
View full Editas Medicine company overviewEditas Medicine annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $607,000 | −$8.2M | −93.12% |
| 2024 | 2024-12-31 | $8.8M | $4.1M | +87.03% |
| 2023 | 2023-12-31 | $4.7M | $601,000 | +14.59% |
| 2022 | 2022-12-31 | $4.1M | −$3.9M | −48.38% |
| 2021 | 2021-12-31 | $8.0M | $815,000 | +11.38% |
| 2020 | 2020-12-31 | $7.2M | $995,000 | +16.13% |
| 2019 | 2019-12-31 | $6.2M | $1.4M | +29.72% |
| 2018 | 2018-12-31 | $4.8M | $2.7M | +130.89% |
| 2017 | 2017-12-31 | $2.1M | −$1.4M | −41.05% |
| 2016 | 2016-12-31 | $3.5M | $2.1M | +144.10% |
| 2015 | 2015-12-31 | $1.4M | $214,000 | +17.58% |
| 2014 | 2014-12-31 | $1.2M | — | — |
Editas Medicine quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $106,000 | $106,000 | — |
| Q1 2026 | 2026-03-31 | $92,000 | −$22,000 | −19.30% |
| Q4 2025 | 2025-12-31 | $60,000 | −$480,000 | −88.89% |
| Q3 2025 | 2025-09-30 | $433,000 | −$2.5M | −85.18% |
| Q2 2025 | 2025-06-30 | $0 | −$3.5M | — |
| Q1 2025 | 2025-03-31 | $114,000 | −$1.8M | −93.91% |
| Q4 2024 | 2024-12-31 | $540,000 | −$767,000 | −58.68% |
| Q3 2024 | 2024-09-30 | $2.9M | $2.7M | +1122.18% |
| Q2 2024 | 2024-06-30 | $3.5M | $2.2M | +162.12% |
| Q1 2024 | 2024-03-31 | $1.9M | $31,000 | +1.68% |
| Q4 2023 | 2023-12-31 | $1.3M | $683,000 | +109.46% |
| Q3 2023 | 2023-09-30 | $239,000 | −$375,000 | −61.07% |
| Q2 2023 | 2023-06-30 | $1.3M | $701,000 | +110.92% |
| Q1 2023 | 2023-03-31 | $1.8M | −$408,000 | −18.15% |
| Q4 2022 | 2022-12-31 | $624,000 | −$2.2M | −78.07% |
| Q3 2022 | 2022-09-30 | $614,000 | −$1.7M | −73.81% |
| Q2 2022 | 2022-06-30 | $632,000 | −$2.1M | −76.63% |
| Q1 2022 | 2022-03-31 | $2.2M | $2.2M | +2576.19% |
| Q4 2021 | 2021-12-31 | $2.8M | $1.5M | +106.76% |
| Q3 2021 | 2021-09-30 | $2.3M | $551,000 | +30.73% |
| Q2 2021 | 2021-06-30 | $2.7M | $863,000 | +46.88% |
| Q1 2021 | 2021-03-31 | $84,000 | −$2.1M | −96.10% |
| Q4 2020 | 2020-12-31 | $1.4M | −$315,000 | −18.63% |
| Q3 2020 | 2020-09-30 | $1.8M | −$452,000 | −20.13% |
| Q2 2020 | 2020-06-30 | $1.8M | $328,000 | +21.68% |
| Q1 2020 | 2020-03-31 | $2.2M | $1.4M | +199.72% |
| Q4 2019 | 2019-12-31 | $1.7M | $276,000 | +19.51% |
| Q3 2019 | 2019-09-30 | $2.2M | $1.3M | +139.34% |
| Q2 2019 | 2019-06-30 | $1.5M | $123,000 | +8.85% |
| Q1 2019 | 2019-03-31 | $718,000 | −$293,000 | −28.98% |
| Q4 2018 | 2018-12-31 | $1.4M | $1.1M | +389.62% |
| Q3 2018 | 2018-09-30 | $938,000 | $186,000 | +24.73% |
| Q2 2018 | 2018-06-30 | $1.4M | $1.0M | +283.98% |
| Q1 2018 | 2018-03-31 | $1.0M | $355,000 | +54.12% |
| Q4 2017 | 2017-12-31 | $289,000 | −$387,000 | −57.25% |
| Q3 2017 | 2017-09-30 | $752,000 | $39,000 | +5.47% |
| Q2 2017 | 2017-06-30 | $362,000 | −$799,000 | −68.82% |
| Q1 2017 | 2017-03-31 | $656,000 | −$287,000 | −30.43% |
| Q4 2016 | 2016-12-31 | $676,000 | $275,000 | +68.58% |
| Q3 2016 | 2016-09-30 | $713,000 | $523,000 | +275.26% |
| Q2 2016 | 2016-06-30 | $1.2M | $626,000 | +117.01% |
| Q1 2016 | 2016-03-31 | $943,000 | $638,000 | +209.18% |
| Q4 2015 | 2015-12-31 | $401,000 | — | — |
| Q3 2015 | 2015-09-30 | $190,000 | — | — |
| Q2 2015 | 2015-06-30 | $535,000 | — | — |
| Q1 2015 | 2015-03-31 | $305,000 | — | — |
Editas Medicine capital expenditures (capex) trends
Over the last five fiscal years, Editas Medicine's capital expenditures (capex) decreased from $7.2M to $607,000, a change of −$6.6M. The latest reported quarter, Q2 2026, shows $106,000.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Editas Medicine source filings ↗